Paratek Pharmaceuticals (NASDAQ:PRTK) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 6th. Analysts expect Paratek Pharmaceuticals to post earnings of ($0.85) per share for the quarter.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02). The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.10 million. Paratek Pharmaceuticals had a negative return on equity of 106.39% and a negative net margin of 1,961.41%. On average, analysts expect Paratek Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of PRTK stock opened at $7.49 on Friday. The company has a current ratio of 7.88, a quick ratio of 7.88 and a debt-to-equity ratio of 2.37. Paratek Pharmaceuticals has a 1-year low of $7.22 and a 1-year high of $22.80.
In other news, Chairman Michael Bigham sold 16,313 shares of the firm’s stock in a transaction that occurred on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total value of $160,193.66. Following the completion of the transaction, the chairman now owns 213,480 shares of the company’s stock, valued at $2,096,373.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Adam Woodrow sold 8,750 shares of the firm’s stock in a transaction that occurred on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total transaction of $85,925.00. Following the completion of the transaction, the vice president now directly owns 112,917 shares of the company’s stock, valued at approximately $1,108,844.94. The disclosure for this sale can be found here. In the last three months, insiders sold 58,446 shares of company stock valued at $559,369. Insiders own 6.20% of the company’s stock.
An institutional investor recently raised its position in Paratek Pharmaceuticals stock. Bank of New York Mellon Corp grew its holdings in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 10.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 129,044 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,980 shares during the quarter. Bank of New York Mellon Corp owned 0.41% of Paratek Pharmaceuticals worth $1,316,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 77.29% of the company’s stock.
Several research analysts have weighed in on the stock. BidaskClub raised shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 6th. Wedbush set a $20.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 9th. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 19th. Bank of America assumed coverage on shares of Paratek Pharmaceuticals in a research note on Monday, August 27th. They set a “neutral” rating and a $13.00 target price for the company. Finally, Guggenheim set a $26.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $30.29.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Featured Article: Outstanding Shares
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.